Advancing Innovation Through
Federal Partnership
IBG is actively pursuing Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) opportunities to de-risk early-stage development and accelerate clinical translation.
Our Funding Strategy
Milestone-Driven Execution & Federal Alignment IOS Biomedical Group (IBG) structures its development roadmap to align with the high-impact innovation priorities of the National Institutes of Health (NIH) and other federal agencies. While we are an early-stage company, our approach to non-dilutive funding is built on a foundation of rigorous planning and "commercialization logic." We view SBIR/STTR grants not just as funding sources, but as validation mechanisms for our core technologies. Our active pursuit of these awards is focused on:
De-Risking Clinical Translation: Securing resources specifically for high-cost transition points, such as GMP manufacturing and IND-enabling toxicology studies
Measurable Deliverables: Every proposal is built around clear, quantifiable milestones—moving from in silico AI predictions to in vivo animal models, and finally to FDA-cleared human trials
Partner-Friendly Structures: We design our workplans to facilitate seamless collaboration with academic institutions (STTR) and industry partners (SBIR), ensuring clear IP delineations and shared commercial value
Why Partner with Us ?
We may be a young company, but our leadership team possesses deep experience in navigating the federal grant landscape. Potential partners can trust in our ability to write, manage, and execute complex grant-funded projects.
PI Expertise
Our Chief Technical Officer, Dr. Edward Gershburg, brings specific experience as a Principal Investigator on multiple SBIR grants focused on herpes vaccines. His background ensures that our technical aims regarding GMP production are realistic and federally compliant.
Scientific Rigor
Our Chief Scientific Officer, Dr. Gus Kousoulas, has an extensive history of NIH-sponsored research. The foundational preclinical testing for our ViraVac™ platform was developed through robust NIH funding at Louisiana State University, providing a strong data package to support new applications. Collaborative
Innovation
We bring cutting-edge computational capabilities to grant proposals, allowing for "wet lab" validation of AI-discovered targets-a highly attractive model for modern funding agencies.
Why Partner With IBG?
Partner With Us
Let’s Build a Winning Proposal Are you an academic laboratory, university tech-transfer office, or specialized biotech startup seeking a translational partner? IBG is ready to collaborate on concept development, specific aims, and execution planning for upcoming grant cycles. We offer a clear path to commercialization for academic discoveries in virology, viral vectors, and AI/LLM discovery.
Specialty Representative, Migraine - San Francisco/Peninsula, CA
Business HR Manager (Pipeline for future talent) Illinois
